Chromatin remodeling-a novel strategy to control excessive alcohol drinking

Translational Psychiatry

Volumn 3, Issue , 2013, Pages

  Warnault, V ^a   Darcq, E ^a   Levine, A ^b   Barak, S ^a,c   Ron, D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Columbia University ^*  (United States)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

addiction; alcohol; chromatin; DNMT; epigenetic; ethanol; HDAC

Indexed keywords

AZACITIDINE; DNA; DNA METHYLTRANSFERASE; DNA METHYLTRANSFERASE 1; HISTONE DEACETYLASE; HISTONE H4; SACCHARIN; SUCROSE; VORINOSTAT; DNA (CYTOSINE 5 ) METHYLTRANSFERASE 1; DNA (CYTOSINE 5) METHYLTRANSFERASE; DNA (CYTOSINE-5-)-METHYLTRANSFERASE 1; HISTONE; HISTONE DEACETYLASE INHIBITOR;

ALCOHOL CONSUMPTION; ALCOHOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR; BEHAVIOR CONTROL; BINGE DRINKING; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMATIN CONDENSATION; CONTROLLED STUDY; DNA METHYLATION; HISTONE ACETYLATION; MOUSE; NONHUMAN; NUCLEUS ACCUMBENS; ACETYLATION; ANIMAL; ANIMAL BEHAVIOR; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GENETICS; HUMAN; METABOLISM; RAT;

ACETYLATION; ALCOHOLISM; ANIMALS; AZACITIDINE; BEHAVIOR, ANIMAL; CHROMATIN ASSEMBLY AND DISASSEMBLY; DISEASE MODELS, ANIMAL; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; HISTONE DEACETYLASE INHIBITORS; HISTONES; HUMANS; MICE; RATS;

EID: 84874311316     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2013.4     Document Type: Article

References (70)

1. Collins PY, Patel V, Joestl SS, March D, Insel TR, Daar AS et al. Grand challenges in global mental health. Nature 2011; 475: 27-30.
2. World Health Organization (WHO) Global Status Report on Alcohol and Health, 2011. World Health Organization: Geneva, Switzerland.
3. Nutt DJ, King LA, Phillips LD. Drug harms in the UK: a multicriteria decision analysis. Lancet 2010; 376: 1558-1565.
4. Wang J, Yuan W, Li MD. Genes and pathways co-associated with the exposure to multiple drugs of abuse, including alcohol, amphetamine/methamphetamine, cocaine, marijuana, morphine, and/or nicotine: a review of proteomics analyses. Mol Neurobiol 2011; 44: 269-286.
5. Ron D, Messing RO. Signaling pathways mediating alcohol effects. Curr Top Behav Neurosci 2011; 13: 87-126.
6. Riccio A. Dynamic epigenetic regulation in neurons: enzymes, stimuli and signaling pathways. Nat Neurosci 2010; 13: 1330-1337.
7. Broide RS, Redwine JM, Aftahi N, Young W, Bloom FE, Winrow CJ. Distribution of histone deacetylases 1-11 in the rat brain. J Mol Neurosci 2007; 31: 47-58.
8. Chen ZX, Riggs AD. DNA methylation and demethylation in mammals. J Biol Chem 2011; 286: 18347-18353.
9. Nan X, Ng HH, Johnson CA, Laherty CD, Turner BM, Eisenman RN et al. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 1998; 393: 386-389.
10. Robison AJ, Nestler EJ. Transcriptional and epigenetic mechanisms of addiction. Nat Rev Neurosci 2011; 12: 623-637.
11. Tsankova N, Renthal W, Kumar A, Nestler EJ. Epigenetic regulation in psychiatric disorders. Nat Rev Neurosci 2007; 8: 355-367.
12. Pandey SC, Ugale R, Zhang H, Tang L, Prakash A. Brain chromatin remodeling: a novel mechanism of alcoholism. J Neurosci 2008; 28: 3729-3737.
13. Ponomarev I, Wang S, Zhang L, Harris RA, Mayfield RD. Gene coexpression networks in human brain identify epigenetic modifications in alcohol dependence. J Neurosci 2012; 32: 1884-1897.
14. Bleich S, Lenz B, Ziegenbein M, Beutler S, Frieling H, Kornhuber J et al. Epigenetic DNA hypermethylation of the HERP gene promoter induces down-regulation of its mRNA expression in patients with alcohol dependence. Alcohol Clin Exp Res 2006; 30: 587-591.
15. Bonsch D, Lenz B, Fiszer R, Frieling H, Kornhuber J, Bleich S. Lowered DNA methyltransferase (DNMT-3b) mRNA expression is associated with genomic DNA hypermethylation in patients with chronic alcoholism. J Neural Transm 2006; 113: 1299-1304.
16. Bonsch D, Lenz B, Kornhuber J, Bleich S. DNA hypermethylation of the alpha synuclein promoter in patients with alcoholism. Neuroreport 2005; 16: 167-170.
17. Bonsch D, Lenz B, Reulbach U, Kornhuber J, Bleich S. Homocysteine associated genomic DNA hypermethylation in patients with chronic alcoholism. J Neural Transm 2004; 111: 1611-1616.
18. Szyf M. Epigenetics, DNA methylation, and chromatin modifying drugs. Annu Rev Pharmacol Toxicol 2009; 49: 243-263.
19. Koob GF, Le Moal M. Addiction and the brain antireward system. Annu Rev Psychol 2008; 59: 29-53.
20. Sales AJ, Biojone C, Terceti MS, Guimaraes FS, Gomes MV, Joca SR. Antidepressant-like effect induced by systemic and intra-hippocampal administration of DNA methylation inhibitors. Br J Pharmacol 2011; 164: 1711-1721.
21. Hess-Stumpp H, Bracker TU, Henderson D, Politz O. MS-275, a potent orally available inhibitor of histone deacetylases-the development of an anticancer agent. Int J Biochem Cell Biol 2007; 39: 1388-1405.
22. Sanchis-Segura C, Lopez-Atalaya JP, Barco A. Selective boosting of transcriptional and behavioral responses to drugs of abuse by histone deacetylase inhibition. Neuropsycho-pharmacology 2009; 34: 2642-2654.
23. Covington HE 3rd, Maze I, LaPlant QC, Vialou VF, Ohnishi YN, Berton O et al. Antidepressant actions of histone deacetylase inhibitors. J Neurosci 2009; 29: 11451-11460.
24. Neasta J, Ben Hamida S, Yowell Q, Carnicella S, Ron D. Role for mammalian target of rapamycin complex 1 signaling in neuroadaptations underlying alcohol-related disorders. Proc Natl Acad Sci USA 2010; 107: 20093-20098.
25. Sprow GM, Thiele TE. The neurobiology of binge-like ethanol drinking: Evidence from rodent models. Physiol Behav 2012; 3: 325-331.
26. NIAAA Council Appoves Definition of Binge Drinking. NIAAA News Letter 3 (NIAAA: Rockville, USA, 2004.
27. Agudelo M, Gandhi N, Saiyed Z, Pichili V, Thangavel S, Khatavkar P et al. Effects of alcohol on histone deacetylase 2 (HDAC2) and the neuroprotective role of trichostatin A (TSA). Alcohol Clin Exp Res 2011; 35: 1550-1556.
28. Markou A, Weiss F, Gold LH, Caine SB, Schulteis G, Koob GF. Animal models of drug craving. Psychopharmacology (Berl) 1993; 112: 163-182.
29. Spanagel R. Alcoholism: a systems approach from molecular physiology to addictive behavior. Physiol Rev 2009; 89: 649-705.
30. Kumar A, Choi KH, Renthal W, Tsankova NM, Theobald DE, Truong HT et al. Chromatin remodeling is a key mechanism underlying cocaine-induced plasticity in striatum. Neuron 2005; 48: 303-314.
31. Bie B, Wang Y, Cai YQ, Zhang Z, Hou YY, Pan ZZ. Upregulation of nerve growth factor in central amygdala increases sensitivity to opioid reward. Neuropsychopharmacology 2012; 37: 2780-2788.
32. Heilig M, Egli M. Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms. Pharmacol Ther 2006; 111: 855-876.
33. Romieu P, Deschatrettes E, Host L, Gobaille S, Sandner G, Zwiller J. The inhibition of histone deacetylases reduces the reinstatement of cocaine-seeking behavior in rats. Curr Neuropharmacol 2011; 9: 21-25.
34. Romieu P, Host L, Gobaille S, Sandner G, Aunis D, Zwiller J. Histone deacetylase inhibitors decrease cocaine but not sucrose self-administration in rats. J Neurosci 2008; 28: 9342-9348.
35. Host L, Dietrich JB, Carouge D, Aunis D, Zwiller J. Cocaine self-administration alters the expression of chromatin-remodelling proteins; modulation by histone deacetylase inhibition. J Psychopharmacol 2011; 25: 222-229.
36. Pastor V, Host L, Zwiller J, Bernabeu R. Histone deacetylase inhibition decreases preference without affecting aversion for nicotine. J Neurochem 2011; 116: 636-645.
37. Wolstenholme JT, Warner JA, Capparuccini MI, Archer KJ, Shelton KL, Miles MF. Genomic analysis of individual differences in ethanol drinking: evidence for non-genetic factors in C57BL/6 mice. PLoS ONE 2011; 6: e21100.
38. Mello NK, Negus SS. Preclinical evaluation of pharmacotherapies for treatment of cocaine and opioid abuse using drug self-administration procedures. Neuropsychopharmacology 1996; 14: 375-424.
39. Steensland P, Simms JA, Holgate J, Richards JK, Bartlett SE. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking. Proc Natl Acad Sci USA 2007; 104: 12518-12523.
40. Escher T, Mittleman G. Schedule-induced alcohol drinking: non-selective effects of acamprosate and naltrexone. Addict Biol 2006; 11: 55-63.
41. Czachowski CL, Delory MJ. Acamprosate and naltrexone treatment effects on ethanol and sucrose seeking and intake in ethanol-dependent and nondependent rats. Psychophar-macology (Berl) 2009; 204: 335-348.
42. Beczkowska IW, Bowen WD, Bodnar RJ. Central opioid receptor subtype antagonists differentially alter sucrose and deprivation-induced water intake in rats. Brain Res 1992; 589: 291-301.
43. Bouza C, Angeles M, Munoz A, Amate JM. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. Addiction 2004; 99: 811-828.
44. Johnson BA. Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings. Biochem Pharmacol 2008; 75: 34-56.
45. Spiegel S, Milstien S, Grant S. Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy. Oncogene 2012; 31: 537-551.
46. Thurn KT, Thomas S, Moore A, Munster PN. Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer. Future Oncol 2011; 7: 263-283.
47. Lawless MW, Norris S, O'Byrne KJ, Gray SG. Targeting histone deacetylases for the treatment of disease. J Cell Mol Med 2009; 13: 826-852.
48. Quintas-Cardama A, Santos FP, Garcia-Manero G. Therapy with azanucleosides for myelodysplastic syndromes. Nat Rev Clin Oncol 2010; 7: 433-444.
49. Uchida S, Hara K, Kobayashi A, Otsuki K, Yamagata H, Hobara T et al. Epigenetic status of Gdnf in the ventral striatum determines susceptibility and adaptation to daily stressful events. Neuron 2011; 69: 359-372.
50. Lubin FD, Roth TL, Sweatt JD. Epigenetic regulation of BDNF gene transcription in the consolidation of fear memory. J Neurosci 2008; 28: 10576-10586.
51. Mulligan MK, Rhodes JS, Crabbe JC, Mayfield RD, Adron Harris R, Ponomarev I. Molecular profiles of drinking alcohol to intoxication in C57BL/6J mice. Alcohol Clin Exp Res 2011; 35: 659-670.
52. McBride WJ, Kimpel MW, Schultz JA, McClintick JN, Edenberg HJ, Bell RL. Changes in gene expression in regions of the extended amygdala of alcohol-preferring rats after bingelike alcohol drinking. Alcohol 2010; 44: 171-183.
53. Rodd ZA, Kimpel MW, Edenberg HJ, Bell RL, Strother WN, McClintick JN et al. Differential gene expression in the nucleus accumbens with ethanol self-administration in inbred alcohol-preferring rats. Pharmacol Biochem Behav 2008; 89: 481-498.
54. Mulligan MK, Ponomarev I, Hitzemann RJ, Belknap JK, Tabakoff B, Harris RA et al. Toward understanding the genetics of alcohol drinking through transcriptome meta-analysis. Proc Natl Acad Sci USA 2006; 103: 6368-6373.
55. Edenberg HJ, Strother WN, McClintick JN, Tian H, Stephens M, Jerome RE et al. Gene expression in the hippocampus of inbred alcohol-preferring and-nonpreferring rats. Genes Brain Behav 2005; 4: 20-30.
56. Kimpel MW, Strother WN, McClintick JN, Carr LG, Liang T, Edenberg HJ et al. Functional gene expression differences between inbred alcohol-preferring and-non-preferring rats in five brain regions. Alcohol 2007; 41: 95-132.
57. McBride WJ, Kimpel MW, McClintick JN, Ding ZM, Hyytia P, Colombo G et al. Gene expression in the ventral tegmental area of 5 pairs of rat lines selectively bred for high or low ethanol consumption. Pharmacol Biochem Behav 2012; 102: 275-285.
58. Lubin FD. Epigenetic gene regulation in the adult mammalian brain: multiple roles in memory formation. Neurobiol Learn Mem 2011; 96: 68-78.
59. He DY, Neasta J, Ron D. Epigenetic regulation of BDNF expression via the scaffolding protein RACK1. J Biol Chem 2010; 285:19043-19050.
60. Jeanblanc J, He DY, Carnicella S, Kharazia V, Janak PH, Ron D. Endogenous BDNF in the dorsolateral striatum gates alcohol drinking. J Neurosci 2009; 29: 13494-13502.
61. Jeanblanc J, He DY, McGough NN, Logrip ML, Phamluong K, Janak PH et al. The dopamine D3 receptor is part of a homeostatic pathway regulating ethanol consumption. J Neurosci 2006; 26:1457-1464.
62. Logrip ML, Janak PH, Ron D. Dynorphin is a downstream effector of striatal BDNF regulation of ethanol intake. FASEB J 2008; 22: 2393-2404.
63. McGough NN, He DY, Logrip ML, Jeanblanc J, Phamluong K, Luong K et al. RACK1 and brain-derived neurotrophic factor: a homeostatic pathway that regulates alcohol addiction. J Neurosci 2004; 24:10542-10552.
64. Barak S, Carnicella S, Yowell QV, Ron D. Glial cell line-derived neurotrophic factor reverses alcohol-induced allostasis of the mesolimbic dopaminergic system: implications for alcohol reward and seeking. J Neurosci 2011; 31: 9885-9894.
65. Carnicella S, Ahmadiantehrani S, Janak PH, Ron D. GDNF is an endogenous negative regulator of ethanol-mediated reward and of ethanol consumption after a period of abstinence. Alcohol Clin Exp Res 2009; 33:1012-1024.
66. Logrip ML, Janak PH, Ron D. Escalating ethanol intake is associated with altered corticostriatal BDNF expression. J Neurochem 2009; 109:1459-1468.
67. Carnicella S, Kharazia V, Jeanblanc J, Janak PH, Ron D. GDNF is a fast-acting potent inhibitor of alcohol consumption and relapse. Proc Natl Acad Sci USA 2008; 105: 8114-8119.
68. Prakash A, Zhang H, Pandey SC. Innate differences in the expression of brain-derived neurotrophic factor in the regions within the extended amygdala between alcohol preferring and nonpreferring rats. Alcohol Clin Exp Res 2008; 32: 909-920.
69. Pandey SC, Zhang H, Roy A, Misra K. Central and medial amygdaloid brain-derived neurotrophic factor signaling plays a critical role in alcohol-drinking and anxiety-like behaviors. J Neurosci 2006; 26: 8320-8331.
70. Enoch MA, Goldman D. Problem drinking and alcoholism: diagnosis and treatment. Am Fam Physician 2002; 65: 441-448.